STOCK TITAN

Odyssey Therapeutics (ODTX) SEC Filings

ODTX NASDAQ
Rhea-AI Summary

Odyssey Therapeutics, Inc. (ODTX) ownership disclosures list FMR LLC and Abigail P. Johnson as each beneficially owning 6,239,237 shares, or 13.0% of the common stock. FMR LLC reports sole voting power over 6,239,231 shares and sole dispositive power over 6,239,237 shares; Abigail P. Johnson reports zero sole voting power and sole dispositive power over 6,239,237 shares. Fidelity Growth Company Commingled Pool is identified as having an interest in 2,892,724 shares, or 6.0% of outstanding common stock at September 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
ownership
-
Rhea-AI Summary

Odyssey Therapeutics, Inc. reported a third-quarter 2026 net loss of $53.059 million, compared with $35.462 million in 2025; nine-month net loss was $144.109 million versus $115.132 million. Collaboration revenue was $0 for the nine months, compared with $2.976 million in 2025, and $0 for the quarter versus $99,000.

Research and development expenses were $42.121 million in the quarter versus $26.325 million, while nine-month operating cash use was $117.085 million compared with $104.139 million. Cash, cash equivalents and marketable securities totaled $387.0 million as of September 30, 2026; management believes these resources will fund operations for at least twelve months from issuance of the statements. Common-stock issuance in the May 2026 IPO generated $288.194 million in net financing cash proceeds.

Odyssey is a clinical-stage biopharmaceutical company with no approved products or product-sales revenue. OD-001 has presented efficacy and supporting analyses from the 12-week induction period of its Phase 2a clinical trial; OD-002 has completed IND-enabling studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.60%
Tags
quarterly report
-
Rhea-AI Summary

Odyssey Therapeutics, Inc. reported a third-quarter 2026 net loss of $53.1 million, versus $35.5 million in the same period of 2025. Adjusted net loss was $41.9 million versus $28.7 million. Research and development expense was $42.1 million, compared with $26.3 million, and general and administrative expense was $11.2 million, compared with $10.2 million. Cash, cash equivalents and marketable securities were $387 million as of September 30, 2026, expected to fund operations into the second half of 2028.

Additional Phase 2a induction analyses for OD-001, involving 56 efficacy-evaluable patients with moderate-to-severe ulcerative colitis, were supported by findings across clinical outcomes, biomarkers, mucosal transcriptomics and histologic improvement. Topline results from the Phase 2b monotherapy and Phase 2a vedolizumab-combination trials are expected in the second half of 2027. Odyssey completed IND-enabling studies for OD-002 and expects to start a Phase 1/2a trial in the first half of 2027; healthy-participant data are expected in the second half of 2027.

Odyssey selected a development candidate for OD-004, which is advancing into IND-enabling studies, and appointed Anthony Opipari, M.D., Ph.D., as chief medical officer and Laura Hare as chief people officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.60%
Tags
current report
Rhea-AI Summary

Odyssey Therapeutics, Inc. reported completed Week 12 induction results from its Phase 2a study of oral OD-001 in moderate-to-severe ulcerative colitis. OD-001 met the trial’s primary endpoint, with a mean 2.4-point reduction from baseline in modified Mayo score across the evaluable population (p<0.001). At 20 mg twice daily (n=41), Week 12 clinical remission, clinical response and symptomatic remission were 27%, 61% and 49%; at 10 mg twice daily (n=15), the rates were 20%, 40% and 27%, respectively. The study was open-label without a concurrent placebo control, and the data remain subject to change until database lock.

Odyssey reported changes in inflammatory biomarkers and reductions in inflammatory and fibrosis-associated gene signatures in colonic biopsies. During induction, there were no serious adverse events, serious infections, treatment-related discontinuations or treatment-emergent liver function abnormalities; three events in the 20 mg group (two fevers and one headache) were considered drug-related. Odyssey plans randomized Phase 2b monotherapy and Phase 2a OD-001-plus-vedolizumab studies, with topline induction results expected in the second half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
current report
-
Rhea-AI Summary

Odyssey Therapeutics, Inc. (ODTX) furnished a new corporate presentation outlining clinical data and pipeline plans across its inflammation and immunology programs. The company reported a balance sheet of $433 million in cash as of June 30, 2026, which it expects to fund operations into the second half of 2028.

Lead program OD-001 (RIPK2 inhibitor) showed Phase 2a proof-of-concept in moderate-to-severe ulcerative colitis, with a 27% clinical remission rate and primary and secondary endpoints reported as met in 49 patients completing 12 weeks. OD-001 was well tolerated at 10 mg and 20 mg BID with no severe (grade ≥3) treatment-emergent adverse events or serious adverse events observed.

The pipeline also includes OD-002 (SLC15A4 inhibitor), targeting B‑cell–driven autoimmune disease with a CTA filing planned in the second half of 2026 and a Phase 1/2 start in the first half of 2027, and OD-003 (TNFR2 agonist) in IND‑enabling studies. The presentation details multiple planned OD-001 Phase 2b and combination readouts in 2027–2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.12%
Tags
current report
-
Rhea-AI Summary

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases. Its lead programs are OD-001, an oral RIPK2 inhibitor with phase 2a proof-of-concept in ulcerative colitis, and OD-002, an oral SLC15A4 inhibitor in IND-enabling studies.

For the six months ended June 30, 2026, the company reported no collaboration revenue and a net loss of $91.1 million, compared with a $79.7 million net loss a year earlier, reflecting continued investment in its pipeline and higher non-cash contingent consideration expense.

After a May 2026 IPO and concurrent private placement, Odyssey strengthened its balance sheet, ending June 30, 2026 with $433.1 million in cash, cash equivalents and marketable securities. Management estimates this capital will fund operating expenses and capital expenditures into the second half of 2028, while substantial future losses remain likely.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
quarterly report
Rhea-AI Summary

Odyssey Therapeutics, Inc. reported results for the quarter ended June 30, 2026, with a GAAP net loss of $52.8 million and adjusted net loss of $38.4 million. Cash, cash equivalents and marketable securities were $433.1 million, expected to fund operations into the second half of 2028.

The company is advancing OD-001, a small molecule RIPK2 scaffolding inhibitor, with Phase 2a expansion treatment complete and data accepted for an oral presentation at UEG Week in October. A Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab are expected to start in the second half of 2026, with topline induction data from both in the second half of 2027. OD-002, an oral SLC15A4 inhibitor, is expected to complete IND-enabling studies and file a CTA in the second half of 2026, enabling a Phase 1/2a trial in the first half of 2027. Research and development expenses were $36.2 million and general and administrative expenses were $10.5 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.09%
Tags
current report
-
Rhea-AI Summary

Odyssey Therapeutics furnished a new corporate presentation outlining its immunology and inflammation pipeline and recent clinical data. The deck highlights OD-001, an oral RIPK2 inhibitor, which achieved a 27% clinical remission rate in a 12‑week Phase 2a ulcerative colitis trial in 49 patients, with concordant endoscopic and symptomatic endpoints and a clean safety profile to date. Odyssey also presents OD-002, a small-molecule SLC15A4 inhibitor targeting pathogenic B cells and interferon signaling, and OD-003, a TNFR2 agonist protein designed to expand regulatory T cells in major autoimmune indications. The company reports a cash balance of $464M as of March 31, 2026, pro forma for IPO and private placement, which it believes funds operations into the second half of 2028 while it advances multiple programs toward key Phase 1 and Phase 2 readouts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
current report
-
Rhea-AI Summary

Odyssey Therapeutics reported a net loss of $38.3 million for the quarter ended March 31, 2026, broadly in line with the prior year. Collaboration revenue fell to zero from $1.9 million as prior Pfizer and Johnson & Johnson research agreements were completed.

Research and development expense was $32.3 million and general and administrative expense was $7.4 million, reflecting continued investment in its autoimmune and inflammatory disease pipeline. Cash, cash equivalents and marketable securities totaled $175.7 million at quarter end.

After the quarter, Odyssey completed an IPO and concurrent private placement, raising net proceeds of about $288.7 million. Together with existing cash, management believes this will fund operations for at least twelve months from issuance of these financial statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
quarterly report
Rhea-AI Summary

Odyssey Therapeutics reported first quarter 2026 results and highlighted key clinical and financing milestones. In a Phase 2a monotherapy trial of OD-001 for moderate to severe ulcerative colitis, 27% of 49 treated patients achieved clinical remission after 12 weeks and 61% achieved clinical response, with OD-001 well tolerated at both doses.

As of March 31, 2026, Odyssey held cash, cash equivalents and marketable securities of $175.7 million, and together with $288.7 million of net proceeds from its initial public offering and concurrent private placement, expects funding to last into the second half of 2028, implying a pro-forma cash position of $464M. The company completed an offering of 15,500,000 shares and a private placement of 1,388,889 shares, with underwriters later purchasing 600,000 additional shares at $18.00 per share.

Research and development expenses were $32.3 million versus $38.8 million a year earlier, general and administrative expenses were $7.4 million versus $8.0 million, and net loss was $38.3 million compared to $38.4 million in the prior-year quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
current report

FAQ

How many Odyssey Therapeutics (ODTX) SEC filings are available on StockTitan?

StockTitan tracks 15 SEC filings for Odyssey Therapeutics (ODTX). Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Odyssey Therapeutics (ODTX)?

The most recent SEC filing for Odyssey Therapeutics (ODTX) was filed on November 5, 2026.